Tucatinib Oral Tablet

Phase 2

PFIZER (PFE)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Dec '26

PFEPhase 2$160.0B

Tucatinib Oral Tablet Phase 2 Est. Readout

Tucatinib Oral Tablet• Leptomeningeal Metastasis30

Dec 2026~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Leptomeningeal Metastasis

View Full Landscape

Drug Information

Target Indication

Leptomeningeal Metastasis

Clinical Trial

NCT05800275

Last updated: 10/16/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

PFE

PFIZER

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

DVS-233 SR (desvenlafaxine sustained release)Phase 3

Major Depressive Disorder

brentuximab vedotinPhase 3

Lymphoma, B-Cell

Insulin LisproPhase 3

Diabetes Mellitus

Cyclosporine APhase 3

Renal Transplantation

13 valent pneumococcal conjugate vaccine with Polysorbate 80Phase 3

Vaccines, Pneumococcal

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts